{
  "trial_id": "NCT00283803",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "willingness and ability to sign an informed consent document",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "21 years or of legal age",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "histologically or cytologically documented prostate cancer",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG Performance status score of 0 or 1",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "received at least one cycle of IAS with an LHRH agonist and anti-androgen",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "willingness to remain off chronic NSAIDs (with the exception of ibuprofen or naproxen)",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "patients on low dose aspirin for cardiovascular prevention may be included in the study",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "have not taken sulindac (Clinoril\u2122) on regular basis for any indication for one week prior to enrollment and willing to remain off of sulindac for the duration of the study",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "patients with prior radiation must be 2 weeks from their last radiation-treatment and have recovered from all associated toxicity",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "known hypersensitivity to sulindac (Clinoril\u2122)",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG Performance status score > 1",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "patients previously on SWOG 9346 or 9921 trials, or any other trials using IAS for which adding exisulind may be confounding",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "patients may not have any evidence of hormone-refractory prostate cancer, i.e. 2 consecutive rises in PSA on LHRH agonist and anti-androgen",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "active peptic ulcer disease",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "use of an investigational medication or device within one month of initiating study therapy",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "elevations of serum creatinine to above the upper limit of normal",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "platelet count < 100,000/L; hgb < 9.0 g/dL; absolute neutrophil count < 1500/mm3",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "The patient is a 55 year old man with lower urinary tract symptoms and a history of prostate cancer. He has not taken sulindac on regular basis for any indication in the past week and is willing to remain off of it for the duration of the study.",
  "_meta": {
    "topic_id": "24",
    "trial_id": "NCT00283803",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}